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Background. Despite the introduction of screening bases intrapartum prophylaxis, Streptococcus agalactiae is still an important
etiological agent of perinatal infections. The increasing rate of resistance and the diﬀerences in resistance pattern among countries
suggest that a program of surveillance at the institutional level is important in determining optimal prophylaxis. In contrast,
knowledge on GBS epidemiology in Italy is limited, and no data are available in the Southern region of the country. We sought
to determine the occurrence of resistance to macrolides and clindamycin of GBS isolates in pregnant and nonpregnant women.
Methods.Between2005and2008,1346vaginaland810rectovaginalswabswereobtainedfrompregnantandnot-pregnantwomen.
Results. The occurrence of macrolides and clindamycin resistance was 16.5% in 2005 increasing up to 69.9% in 2008. A high
percentage of isolates was resistant to tetracycline through all the study period with no statistically signiﬁcant annual. Conclusions.
In our cohort, an increase of in vitro resistance of GBS to macrolides and clindamycin is clearly evident. The discordance with
reports from diﬀerent countries emphasize the crucial role of microbiological methods in setting possible therapeutic strategies.
1.Introduction
Among Gram-positive bacteria, Streptococcus agalactiae, also
known as Group B Streptococcus (GBS) is considered a
common commensal of the female urogenital tract and
rectum [1] whose importance is referred to severe neonatal
pathologies by perinatal transmission from women to new-
borns. Neonatal infections by GBS are usually distinguished
in early onset (occurring in the ﬁrst 7 days of life) and late
onset (occurring between 7 days of life and 3 months of age):
this temporal distinction reﬂects diﬀerences in the spectra of
infection [2, 3].
In studies carried out in the 1970s, GBS emerged as
the leading cause of neonatal morbidity and mortality, with
a frequency of 2-3 cases per 1000 live births and case-
fatality ratios of 50% [3, 4]. The vaginal colonization
prevalence among pregnant women varies in European
countriesbetween10and20%,andtheincidenceofneonatal
infections ranges from 0.5 to 2 per 1000 live births [5–8].
Between 1996 and 1997, the American College of Ob-
stetricians and Gynecologists, the Centers for Disease Con-
trolandPrevention,andtheAmericanAcademyofPediatrics
produced recommendations for prevention of perinatal GBS
disease. These guidelines recommended the use of culture-
based screening for GBS colonization between 35 and
37 weeks gestation and the antibiotic prophylaxis of all
colonized women [9, 10].
The intrapartum antibiotic prophylaxis (IAP) for GBS
carriers indicates the use of penicillin (or ampicillin). For
penicillin-allergic women without a history of anaphylaxis,
angioedema, respiratory distress, or urticaria, cefazolin is
the preferred agent. Vancomycin and clindamycin are rec-
ommended for penicillin-allergic women at high risk for
anaphylaxis. The introduction of IAP for GBS carriers has2 Infectious Diseases in Obstetrics and Gynecology
been associated with a substantial decline in the incidence of
early-onset neonatal infections [11].
The purpose of the present study was to assess the
antibiotic susceptibility patterns of GBS isolates obtained
from a heterogeneous female population (pregnant and
nonpregnant) in a region of Southern Italy and to evaluate
whether statistically signiﬁcant changes in GBS antibiotic
resistance regarding macrolides and clindamycin occurred in
the years in order to generate local data for the development
of rational interventions for prevention of GBS infection in
our country.
2.MaterialsandMethods
2.1. Study Population. In the period from January 2005 up
to December 2008, a total of 2156 biological samples (1346
vaginal swabs from nonpregnant women and 810 rectovagi-
nalswabsfrompregnantwomenat35–37weeksofgestation)
were collected in the Microbiology Laboratory of University
Hospital “Federico II”, Naples, Italy. All women gave their
consent to take part in the study. Therapeutic protocols were
not modiﬁed for women enrolled in the study.
2.2. Processing of Samples, Culture of Microorganisms, and
Identiﬁcation Analysis. All swabs were maintained in the
Stuart transport medium and transported to the Microbi-
ology Laboratory. Swabs were plated on several agar media,
including Columbia colistin-nalidixic acid (CNA) agar with
addition of 5% of sheep blood, MacConkey agar, Sabouraud
agar, and chocolate agar and incubated at 37◦C overnight
in aerobic or microaerobic conditions and were examined
microscopically to evaluate the preservation of Lactobacillus
microbial status.
Bacteria were identiﬁed by conventional methods (Gram
stain, catalase test) and automated system (Vitek II, bio-
M´ erieux, France). The identiﬁcation of the Lanceﬁeld anti-
gen was obtained by Streptococcal Grouping Kit (Oxoid,
Hampshire, England).
2.3.AntimicrobialSusceptibilityTestingMethod. Tocheckthe
sensitivity to antimicrobial agents, an automated micro-
dilution method (Vitek II) was utilized. The susceptibility
criteria were in accordance with the National Committee for
Clinical Laboratory Standards Interpretative Criteria [12].
Antibiotics tested were as follows: amoxicillin/clavulanic
acid, ampicillin, cefaclor, cefotaxime, ceftriaxone, clin-
damycin, erythromycin, penicillin, teicoplanin, tetracycline,
trimethoprim/sulfamethoxazole, vancomycin, levoﬂoxacin,
azithromycin, clarithromycin, quinupristin/dalfopristin, and
linezolid.
2.4. Statistical Analysis. Statistical analysis, including com-
parison of proportions and chi-squared test, was applied
throughout the study. A P<0.05 was considered statistically
signiﬁcant.





























































between vaginal and rectal-vaginal swabs) were isolated. The
distributions of swabs, positive cultures, and patients in the
period of study are indicated in Table 1.
Thedistributionofsingle-patientresistantGBSisolatesis
showedinTable 2 aswellasthesusceptibilitypatternoverthe
study period. The antibiotic susceptibility proﬁles indicate
that isolates showed sensitivity to beta-lactams, glycopep-
tides, quinolones, quinupristin-dalfopristin, trimethoprim-
sulfamethoxazole, and linezolid.
The number of isolates resistant to tetracycline was high
through all the study period, indicating not statistically
signiﬁcant ﬂuctuations. Instead, the increment of resistance
to macrolides and clindamycin was statistically signiﬁcant
through the study period (X2 for trend = 8.100, P = 0.004).
The annual increment in percentage of macrolides- and
clindamycin-resistant isolates during the study period is
indicated in Figure 1.
The GBS isolates resistant to tetracycline showed a
MIC value ≥16µg/mL through all the study period. The
MICs obtained for macrolides and clindamycin range from
≤0.25µg/mL to ≥8µg/mL.
4. Discussion
In our experience, in accordance with CDC 2010 guidelines,
penicillin and ampicillin are still the ﬁrst choice for IAP,
followed by ﬁrst-generation cephalosporins as cefazolin in
penicillin allergic women. In fact all GBS isolates were
susceptible to these antibiotics. The prevalence of isolates
resistant to macrolides and clindamycin is considerably high
(55%) and has increased signiﬁcantly from 16.5% to 70%
during the study period (P<0.05).
Although very few women GBS positive give birth to
babies who are infected with GBS, antenatal screening
is routinely performed to reduce the rate of early-onset
infections in newborns. However, there is still controversy
about its prevention since antenatal screening and treatmentInfectious Diseases in Obstetrics and Gynecology 3
Table 1: Distribution of swab type, positive cultures, and number of infected patients.
Year Total swabs N (%) Total positive cultures N (%)
Vaginal-rectal Vaginal Vaginal-rectal Vaginal
2005 76 (7.7%) 153 (13%) 23 (6.4%) 62 (11.9%)
2006 192 (19.5%) 212 (18.1%) 51 (14.3%) 97 (18.6%)
2007 345 (35.1%) 357 (30.4%) 134 (37.5%) 146 (28%)
2008 370 (37.6%) 451 (38.4%) 149 (41.7%) 217 (41.6%)
Total 2156 Total 879
Table 2: Distribution (number and percentage) of resistant GBS strains during the 4-year study period.
2005 2006 2007 2008
positive cultures (85) positive cultures (162) positive cultures (280) positive cultures (366)
N◦ % N◦ % N◦ % N◦ %
A M C0—0—0—0—
A M P0—0—0—0—
C E C 0—0—0—0—
C T X 0—0—0—0—
C R O 0—0—0—0—
CLI 14 16.5 48 29.6 162 57.9 256 69.9
ERY 14 16.5 48 29.6 162 57.9 256 69.9
P E N 0—0—0—0—
T E C 0—0—0—0—
TET 51 60 97 59.9 197 70.4 278 76
S X T 0—0—0—0—
V A N 0—0—0—0—
L V X 0—0—0—0—
AZM 14 16.5 48 29.6 162 57.9 256 69.9
CLR 14 16.5 48 29.6 162 57.9 256 69.9
Q - D 0—0—0—0—
L Z D 0—0—0—0—
AMC=amoxicillin-clavulanicacid;AMP=ampicillin;CEC=cefaclor;CTX =cefotaxime;CRO =ceftriaxone;CLI =clindamycin;ERY=erythromycin;PEN=
penicillin; TEC = teicoplanin; TET = tetracycline;SXT = trimethoprim-sulfamethoxazole; VAN = vancomycin; LVX = levoﬂoxacin; AZM = azithromycin; CLR
= clarithromycin; Q-D = quinupristin-dalfopristin; LZD = linezolid.
may carry disadvantages for the mother and the baby. The
usual recommendation for prevention of GBS transmission
from colonized women to their infants during labour is to
administer intravenous penicillin or ampicillin every 4h for
the duration of labour [11].
On the maternal side, IAP’s risks are allergic reactions.
Even if there are some anecdotal reports of maternal
mortality due to anaphylaxis, usually allergic reactions are
not severe and mainly with maculopapular rushes [11, 13,
14].
Onthefetal/neonatalside,thereisnoriskforanaphylaxis
resulting from IAP, but there is a growing concern about
the development of antibiotic resistance among GBS isolates
and other pathogens. The increased resistance may have two
eﬀects: exposure of neonates to antibiotic-resistant path-
ogens with development of intractable sepsis and reduction
of the chance to prevent maternal fetal transmission by GBS.
Two recent published surveys have demonstrated that
in England and France neonatal infections are still mainly
caused by GBS, and the current policy of GBS maternal pro-
phylaxis is not associated with an excessive risk of pathogen
resistance [15, 16]. The incidence of early-onset sepsis (EOS)
ranged among 0.9 to 1.9/1000 live births, and GBS (58–
62%) and Escherichia coli (18–25%) were the most common
organisms. About the antibiotic resistance, the majority of
pathogens(95%)causingEOSweresusceptibletocommonly
used empiric ﬁrst-line antibiotic combinations.
About the risk of reduced eﬃcacy of IAP for GBS, data
arereassuring.Worldwide,therehavebeenonlyafewreports
of penicillin resistance [17, 18] or elevated MIC [19, 20]
secondary to the alterations in penicillin-binding proteins
(PBP). In the majority of isolates with alteration of PBP, the
measured MICs were just at the threshold of susceptibility,
but the clinical signiﬁcance of higher MIC values remains
unclear. Elevated MICs to cefazolin also were reported, but
as penicillin/ampicillin, the clinical signiﬁcance of higher
MICs to cefazolin among GBS isolates remains unclear
[11]. In our experience GBS isolates have not yet developed4 Infectious Diseases in Obstetrics and Gynecology
any resistance against penicillin and ampicillin and ﬁrst-
generation cephalosporin. This aspect is very reassuring if
we consider that these antibiotics are constantly indicated
as ﬁrst choice in women positive for GBS. Their eﬃcacy as
IAP was demonstrated for the ﬁrst time in clinical trials by
Boyer and Gotoﬀ [21] in 1986 and by Garland and Fliegner
[22] in 1991. On the contrary the eﬃcacy of alternatives to
penicillin/ampicillinforallergicwomen(including cefazolin,
clindamycin, erythromycin, and vancomycin) has not been
tested in controlled trials. About cephalosporin, it has been
supposed that, given the similar activity, pharmacokinetics,
and dynamics of cefazolin to penicillin/ampicillin, it could
be a second-line antibiotic in penicillin allergic women with
low risk of anaphylaxis. As long as allergic women with
high risk of anaphylaxis, the guidelines suggest the use
of clindamycin/erythromycin or vancomycin although their
ability to reach bactericidal levels in the fetal circulation
a n da m n i o t i cﬂ u i da r ev e r yl i m i t e d[ 23–25]. The choice of
one or another antibiotics is made on the results of antimi-
crobial susceptibility testing. These women should receive
clindamycin if their GBS isolate is susceptible to clindamycin
and erythromycin or if it is resistant to erythromycin but
sensitive to clindamycin with negative testing for inducible
clindamycin resistance. Otherwise, if susceptibility to both
agentsisunknown,thesewomenshouldreceivevancomycin.
At the moment, erythromycin is no longer considered an
alternative for IAP in penicillin-allergic women at high risk
for anaphylaxis [11].
Starting from our data, in the next future the problems
related with antibiotic resistance will become bigger and
bigger and the treatment of allergic women will be a major
obstacle. In fact during the study period, the number of
colonized women is increased from 85 to 366. If we consider
stable the number of allergic women at risk for anaphylaxis,
we will have that more and more women will be treated with
alternative antibiotics which will be potentially ineﬀective or
will increase the spectrum of resistance.
In reports published, the prevalence of resistance among
GBS ranged from 7% to 25% for erythromycin and from 3%
to 21% for clindamycin [26, 27]. Resistance to erythromycin
was frequently but not always associated with clindamycin
resistance. In our series resistance was always to both
erythromycin and clindamycin, and the prevalence was
considerably higher, ranging from 16.4% to 70% in the
study period, showing a statistically signiﬁcant increment
(P<0.05). This ﬁnding is very far from previous reports
from other nations indicating signiﬁcant country variations
and supporting the usefulness of research about GBS in
each population. The increased resistance to macrolides,
particularly to erythromycin observed all over the world,
can be ascribable to the treatment of Chlamydia infections
of the lower reproductive tract [28]; however we have
no explanation for the higher rate of resistance in our
population. An hypothesis is that the variation may be due
to diﬀe r e n c e si nt e c h n i q u e sa sw e l la sc h a r a c t e r i s t i c so ft h e
population investigated.
The prevalence of GBS-positive women observed in our
population is higher even when compared with other Italian
studies. In the study of Savoia et al. [29], among 300
pregnant women screened, 73 single-patient GBS isolates
were collected and only 3 out of 73 (4.1%) were resistant to
erythromycin. Also the lincosamides (lincomycin) were less
eﬃcient. Overall the infection prevalence was 18.2% versus
41%observedinourpopulation(879infectedpatientsoutof
2156 patients). In another Italian study by Sensini et al. [6],
the prevalence of GBS was even lower (11%). Comparing the
numbers, an hypothesis is that the prevalence of infection is
growing over the years (11% versus 18.2 versus 41%).
The main limitations of our study are the diﬀerence in
surveillance population (pregnant and nonpregnant) and,
for pregnant women, the lack of clinical data about the
pregnancy and neonatal outcome. This aspect could be a
starting point for new research since to date whether in vitro
resistance of GBS has direct clinical implications remains
unclear.
5. Conclusion
Antibiotics are used for both GBS prevention and treatment.
The introduction of IAP for GBS carriers has been associated
with a substantial decline in the incidence of early-onset
neonatal infections. However, the potential side eﬀect of the
protocol is the risk of development of pathogen resistance
to antibiotics. Until now GBS isolates remain susceptible to
penicillin and ampicillin and ﬁrst-generation cephalosporin,
but resistance to alternative agents as erythromycin and
clindamycin is an increasing concern. In fact these agents are
suggested in women with high risk of anaphylaxis although
their ability to reach bactericidal levels in the fetal circulation
and amniotic ﬂuid is very limited. Comparing reports of the
literature, epidemiology of infection, and resistance pattern
change substantially among countries suggesting the need of
local study to map the prevalence of resistant isolates.
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